Juno Pharmaceuticals is excited to announced it has been appointed as the exclusive distributor in Australia and New Zealand for Hexvix® (hexaminolevulinate hydro-chloride), an innovative breakthrough technology to aid in the diagnosis and management of non-muscle-invasive bladder cancer. The registration process will begin immediately with hopes that this product will be registered in 2016.

In Australia, each year over 2,500 people are diagnosed with bladder cancer, and unfortunately over 1,000 people die.

Hexvix®is designed to selectively target malignant cells in the bladder and induce fluorescence during a cystoscopic procedure using a blue-light enabled cystoscope. Using Hexvix® as an adjunct to standard white-light cystoscopy enables the urologist to better detect and remove lesions. Hexvix® is currently approved in Europe and the USA.